These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35563278)

  • 1. Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA.
    Dreymann N; Wuensche J; Sabrowski W; Moeller A; Czepluch D; Vu Van D; Fuessel S; Menger MM
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.
    Dupont DM; Madsen JB; Hartmann RK; Tavitian B; Ducongé F; Kjems J; Andreasen PA
    RNA; 2010 Dec; 16(12):2360-9. PubMed ID: 20962041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.
    Botkjaer KA; Deryugina EI; Dupont DM; Gårdsvoll H; Bekes EM; Thuesen CK; Chen Z; Ploug M; Quigley JP; Andreasen PA
    Mol Cancer Res; 2012 Dec; 10(12):1532-43. PubMed ID: 23038812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aptamer-Based Sandwich Assay Formats for Detection and Discrimination of Human High- and Low-Molecular-Weight uPA for Cancer Prognosis and Diagnosis.
    Dreymann N; Sabrowski W; Danso J; Menger MM
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
    De Souza M; Matthews H; Lee JA; Ranson M; Kelso MJ
    Bioorg Med Chem; 2011 Apr; 19(8):2549-56. PubMed ID: 21454081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers.
    Damare J; Brandal S; Fortenberry YM
    Nucleic Acid Ther; 2014 Aug; 24(4):239-49. PubMed ID: 24922319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites.
    Dupont DM; Thuesen CK; Bøtkjær KA; Behrens MA; Dam K; Sørensen HP; Pedersen JS; Ploug M; Jensen JK; Andreasen PA
    PLoS One; 2015; 10(3):e0119207. PubMed ID: 25793507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis.
    Mukhina S; Stepanova V; Traktouev D; Poliakov A; Beabealashvilly R; Gursky Y; Minashkin M; Shevelev A; Tkachuk V
    J Biol Chem; 2000 Jun; 275(22):16450-8. PubMed ID: 10749881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
    J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
    Ploug M; Ellis V; Danø K
    Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
    Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
    J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site. An explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules.
    Novokhatny V; Medved L; Lijnen HR; Ingham K
    J Biol Chem; 1995 Apr; 270(15):8680-5. PubMed ID: 7721771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.